Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more
Bafna Pharmaceuticals Limited (BAFNAPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.030x
Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) has a cash flow conversion efficiency ratio of 0.030x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹24.82 Million) by net assets (₹823.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bafna Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Bafna Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bafna Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bafna Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
-1.064x |
|
Entre Cua Socimi
MC:YENT
|
0.013x |
|
New Concept Energy Inc
NYSE MKT:GBR
|
-0.011x |
|
PMVCD
PINK:PMVCD
|
-0.024x |
|
Richmond Vanadium Technology Ltd
AU:RVT
|
-0.025x |
|
ADUX S.A. EO -25
F:HJMA
|
N/A |
|
Trius Investments Inc
V:TRU
|
-0.139x |
|
Openn Negotiation Ltd
AU:OPN
|
0.905x |
Annual Cash Flow Conversion Efficiency for Bafna Pharmaceuticals Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Bafna Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹848.07 Million | ₹195.29 Million | 0.230x | +96.27% |
| 2024-03-31 | ₹808.39 Million | ₹94.85 Million | 0.117x | +74.02% |
| 2023-03-31 | ₹734.55 Million | ₹49.52 Million | 0.067x | -57.06% |
| 2022-03-31 | ₹619.64 Million | ₹97.28 Million | 0.157x | +165.49% |
| 2021-03-31 | ₹567.71 Million | ₹-136.09 Million | -0.240x | +64.19% |
| 2020-03-31 | ₹511.95 Million | ₹-342.68 Million | -0.669x | -606.06% |
| 2019-03-31 | ₹188.52 Million | ₹-17.87 Million | -0.095x | +49.95% |
| 2018-03-31 | ₹372.02 Million | ₹-70.47 Million | -0.189x | -742.20% |
| 2017-03-31 | ₹421.12 Million | ₹-9.47 Million | -0.022x | -242.15% |
| 2016-03-31 | ₹575.71 Million | ₹9.11 Million | 0.016x | -89.21% |
| 2015-03-31 | ₹727.13 Million | ₹106.65 Million | 0.147x | +536.93% |
| 2014-03-31 | ₹697.48 Million | ₹16.06 Million | 0.023x | -95.71% |
| 2013-03-31 | ₹683.04 Million | ₹366.32 Million | 0.536x | +460.94% |
| 2012-03-31 | ₹646.17 Million | ₹-96.01 Million | -0.149x | -26.74% |
| 2011-03-31 | ₹541.89 Million | ₹-63.53 Million | -0.117x | -708.49% |
| 2010-03-31 | ₹410.05 Million | ₹-5.95 Million | -0.015x | +96.00% |
| 2009-03-31 | ₹385.23 Million | ₹-139.82 Million | -0.363x | -105.51% |
| 2008-03-31 | ₹118.55 Million | ₹-20.94 Million | -0.177x | -115.97% |
| 2007-03-31 | ₹91.39 Million | ₹101.06 Million | 1.106x | +1151.53% |
| 2006-03-31 | ₹56.78 Million | ₹-5.97 Million | -0.105x | +83.71% |
| 2005-03-31 | ₹42.55 Million | ₹-27.46 Million | -0.646x | -- |